SEC Form 4/A · accession 0001104659-15-022205

ARRAY BIOPHARMA INC · ARRY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Officer — CEO · Director

Period of report

Mar 1, 2015

Accepted (ET)

Mar 24, 2015 · 7:59 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001100412

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—		—	32,541	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F2	—	Mar 1, 2015	M	77,881	D	—	Aug 18, 2018	Common Stock	77,881	77,881	D

F1This amended Form 4 is filed to correct the Reporting Person's holdings after the transactions reported on the Form 4 filed March 4, 2015. All other data reported was correct. Includes shares purchased pursuant to the Issuer's Employee Stock Purchase Plan as follows: 3,523 shares purchased December 31, 2012, 6,287 shares purchased December 31, 2013 and 5,407 shares purchased December 31, 2014.
F2Footnote 4 referenced in line 1 of Table II in Form 4 filed March 4, 2015 by the reporting person is amended in its entirety to read: Restricted Stock Units ("RSUs") were awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. RSUs representing 77,881 shares of common stock vested on March 1, 2015 and 77,881 shares remain unvested and subject to achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, in each case subject to continued service with the Issuer as of each vesting date.